Also known as: Prolia / Xgeva
Denosumab is a fully human monoclonal antibody (IgG2) that targets RANKL (receptor activator of nuclear factor kappa-B ligand), inhibiting osteoclast formation and function to reduce bone resorption. It is used for osteoporosis, bone metastases, and giant cell tumor of bone. Mediocon Inc supplies pharmaceutical-grade Denosumab for bulk pharma manufacturing.
Key Features
Applications
Why Choose Mediocon
| Parameter | Specification |
|---|---|
| Assay | 99.0% Min. |
| Loss on Drying | NMT 1.0% |
| Melting Point | N/A (biologic) |
| Heavy Metals | Complies |
| pH | N/A |
| Microbial Limits | Complies with pharmacopoeia |
| Identification | IR, HPLC Compliant |
| Packing | 25 kg HDPE drums / as per requirement |
Mediocon Inc is a GMP-certified API manufacturer and bulk pharmaceutical ingredient supplier based in Aurangabad, Maharashtra, India. We specialise in supplying Denosumab (CAS 615258-40-7) and over 1,000 other Active Pharmaceutical Ingredients, excipients, herbal extracts, and nutraceutical ingredients to pharmaceutical manufacturers worldwide.
Our Denosumab is manufactured under strict quality management protocols compliant with WHO-GMP, ISO 9001:2015, and major pharmacopoeial standards (IP, BP, USP, EP). Every batch undergoes full analytical testing — identity (IR/HPLC), assay, related substances, residual solvents (ICH Q3C), heavy metals, and microbial limits — before release with a Certificate of Analysis.
Export Markets
Quality & Compliance